Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Equity Bottom-Up

<ul><li>CYB003’s Phase 3 trial begins. In just three years since filing its Investigational New Drug Application (IND) for its adjunctive CYB003 program, now labeled PARADIGMTM (an allusion to CYB003’s potential for a paradigm shift in treating depression), Cybin has initiated the first of three Phase 3 pivotal efficacy studies.</li><li>Pivotal first study is underway, with top-line results expected in 2026.</li><li>The first study (named APPROACH) is a two-arm study involving a targeted 220 participants with moderate to severe MDD (MADRS≥24) who are on a stable dose of antidepressant medication but are responding inadequately.</li></ul>

CYB003’s Phase 3 trial begins. In just three years since filing its Investigational New Drug Application (IND) for its adjunctive CYB003 program, now labeled PARADIGMTM (an allusion to CYB003’s potential for a paradigm shift in treating depression), Cybin has initiated the first of three Phase 3 pivotal efficacy studies.Pivotal first study is underway, with top-line results expected in 2026.The first study (named APPROACH) is a two-arm study involving a targeted 220 participants with moderate to severe MDD (MADRS≥24) who are on a stable dose of antidepressant medication but are responding inadequately.

Cybin, Inc. - CYB003 フェーズ3試験開始